key: cord-0731811-4xvy50hd
authors: Koseki, Takenao; Nakajima, Kazuki; Iwasaki, Hitoshi; Yamada, Shigeki; Takahashi, Kazuo; Doi, Yohei; Mizuno, Tomohiro
title: Baseline uric acid levels and steady-state favipiravir concentrations are associated with occurrence of hyperuricemia among COVID-19 patients
date: 2021-12-12
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.12.324
sha: 2929bb16405a235d83b1e3a3d2f067f0ac2e468c
doc_id: 731811
cord_uid: 4xvy50hd

Objectives Favipiravir is an antiviral which is being evaluated for the treatment of COVID-19. Use of favipiravir is associated with elevation of serum uric acid levels. Risk factors for the occurrence of hyperuricemia are unclear. Methods Specimens from patients who received 10 days of favipiravir in a previous clinical trial (jRCTs041190120) were used. Serum favipiravir concentrations were measured by LC-MS. Factors associated with development of hyperuricemia were investigated by the logistic regression analysis. Optimal cut-off values for the baseline serum uric acid levels and steady-state serum favipiravir concentrations in predicting the occurrence of hyperuricemia were determined by ROC curve analysis. Results Among 66 COVID-19 patients who were treated with favipiravir for 10 days, the steady-state serum favipiravir concentrations were significantly correlated with serum uric acid levels. High baseline serum uric acid levels and steady-state serum favipiravir concentrations during therapy were factors associated with the development of hyperuricemia. The cut‑off baseline serum uric acid level and steady-state serum favipiravir concentration during favipiravir administration to predict hyperuricemia were 3.7 mg/dL and 46.14 μg/mL, respectively. Conclusions Patients who have high baseline serum uric acid levels or achieve high steady-state serum favipiravir concentrations during therapy are susceptible to hyperuricemia.

Favipiravir (FVP) is an oral RNA-dependent RNA polymerase inhibitor that is being evaluated as an antiviral for the treatment of coronavirus infectious disease 2019 (COVID-19) (Alam et al., 2021) . In Elevation of serum UA levels has also been reported in several clinical trials of FVP against COVID-19 (Doi et al., 2020 , Udwadia et al., 2021 , Zhao et al., 2021 . Furthermore, a COVID-19 patient with history of hyperuricemia developed acute gouty arthritis upon receiving FVP . We previously conducted a randomized, multi-center open-label clinical trial of FVP against COVID-19. In this trial, FVP 1,800 mg twice on the first day followed by 800 mg twice daily for up to an additional 9 days induced hyperuricemia in 69 out of 82 patients (84.1%) (Doi et al., 2020) .

The dose of FVP in this trial was higher than that in other studies such as the 312 Study for influenza.

In addition, FVP administration was significantly more likely to induce elevation of serum UA levels than placebo or other candidate antivirals for COVID-19 (5.8% vs 1.3%) in a systematic review 7 (Pilkington et al., 2020) . Morikawa et al. reported that a high serum FVP level (20 μg/mL or more) was associated with elevation of UA levels in COVID-19 treatment in a single-center cohort of 27 patients (Morikawa et al., 2021) . These studies suggest that the risk of developing hyperuricemia may depend on the serum FVP concentrations. However, factors related to the elevation of serum UA levels in COVID-19 patients treated with FVP remain unclear overall. Herein, we investigated the factors associated with the occurrence of hyperuricemia in COVID-19 patients from this clinical trial cohort (Doi et al., 2020) .

The clinical dataset from a previously conducted multi-center, open-label, randomized clinical trial was used (jRCTs041190120) (Doi et al., 2020) . Briefly, patients with asymptomatic or mild COVID-19 were recruited, registered and given FVP that was dosed at 1,800 mg twice orally at least 4 h apart on the first day, followed by 800 mg orally twice daily for up to an additional 9 days. The patients were randomized to start FVP either immediately or five days after randomization, with the intention to continue FVP for a total of 10 days in both groups. Of the 89 patients who participated in the clinical trial and assigned to either the immediate or delayed treatment group, 66 were included in this substudy after excluding 23 patients for the following reasons: 1) one patient withdrew from the study, 2) 20 patients did not take FVP for the full 10 days as intended by the study protocol, 3) 2 8 patients had no baseline serum UA levels or FVP concentrations. Serum samples for measurement of laboratory values and FVP concentrations were collected just prior to the first dose of FVP, on the sixth day of FVP administration which represents the steady state (Morikawa et al., 2021) , and on the eleventh day, which is one day after the last FVP dose. To investigate the factors contributing to the occurrence of hyperuricemia, patients were divided into two groups: those with hyperuricemia (UA >10 mg/dL) on the sixth-day or eleventh-day samples, and those without. The definition of hyperuricemia was adopted from the definition of Grade 4 hyperuricemia (UA >10 mg/dL) in the Common Terminology Criteria for Adverse Events (CTCAE) criteria version 4.0.

For the measurement of serum FVP concentration, surplus serum samples from the underlying clinical trial were used. In preparation, 200 l of acetonitrile, 20 l of 75% isopropanol and the internal standard solution (10 µg/mL [ 13 C, 15 N]-FVP in acetonitrile) were added to 50 l of serum.

The mixture was then vortexed and centrifuged (15,000 × g) for 5 min. The supernatant was collected in a new 1.5-mL polypropylene tube, and an aliquot of 1 l was injected into a triple quadrupole mass spectrometer LCMS8060NX coupled to a Nexera X2 liquid chromatography system (Shimadzu). The analytes were separated on a Shim-pack Scepter C18-120 column (50 mm × 2.1 mm i.d., 3 μm; Shimazdu GLC), using a mobile phase of (A) 0.05 % formic acid and (B) 0.05 % formic acid in acetonitrile. The gradients were follows: 5 % (v/v) solvent B for 0.3 min, 5-30 % For the LC-MS method, intra-day and inter-day reproducibility was assessed by analyzing three and seven replicates at the lower level of quantification (LLOQ: 0.05 μg/ml) in addition to two concentrations (1 μg/ml and 10 μg/ml), respectively (Supplementary Table 1 ). The accuracy was defined as the deviation between the true and the measured value expressed as percentage, and the precision was characterized by the relative standard deviation. The linear range of calibration curve was also evaluated by plotting the peak area ratios of FVP/[ 13 C, 15 N]-FVP versus the concentration ratios (Supplementary Figure 1 ).

We performed statistical analysis using EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria, version 4.0.3). More precisely, it is a modified version of R commander (version 1.54) designed to add statistical functions frequently used in biostatistics (Kanda, 2013) .

, laboratory values, and serum FVP concentration) were expressed as the median and range, and compared between patients with or 10 without hyperuricemia (UA >10 mg/dL) using Mann-Whitney U-test. The categorical variables were summarized by presenting the frequency and proportion of patients and compared using Fisher's exact test. Friedman rank sum test was performed to evaluate the changes in the serum UA and FVP levels between the baseline, sixth-day and eleventh-day samples. Mann-Whitney U-test was used for comparing the serum FVP levels between patients with or without hyperuricemia (UA >10 mg/dL) on the sixth or eleventh day. Spearman's correlation test was performed for correlation analysis.

Logistic regression analysis was performed for the multivariate analysis for the occurrence of hyperuricemia (UA >10 mg/dL) on either the sixth or eleventh day. The cut-off values for the baseline serum UA level and the steady-state serum FVP concentration in predicting the occurrence hyperuricemia was evaluated by receiver operating characteristic (ROC) curve. The area under the curve (AUC) was calculated with corresponding sensitivity and specificity. Results were considered statistically significant at p-values < 0.05.

This study included 66 COVID-19 patients who received FVP for 10 days as part of the clinical trial ( Figure 1 ). The baseline characteristics of the subjects are shown in Table 1 . The median age was 48.5 years (range, 24.0-86.0), and the median BMI was 22.8 kg/m 2 (range, 16.9-37.1). Forty patients (60.6%) were male and 26 patients (39.4%) were female. The median baseline serum UA level was 4.6 mg/dL (range, 1.7-7.6).

Patients with or without subsequent hyperuricemia were divided into non-hyperuricemia (n=26) and hyperuricemia (n=40) groups, respectively. The two groups were comparable in their demographic and laboratory values, except for serum AST and UA levels ( Table 1) 

The median serum UA levels were elevated at 9.7 mg/dL (range, 5.0-15.6) on the sixth day (steady state during FVP therapy) and 10.3 mg/dL (range, 3.7-13.6) on the eleventh day (one day after completion of FVP therapy), respectively (p<0.01) (Figure 2A ).

Serum FVP levels in plasma were quantified by validated LC-MS methods (Supplementary Table 1 and Supplementary Figure 1) . Overall, the median serum FVP concentrations were 0.00 μg/mL (range, 0.00-0.02) at baseline, 48.31 μg/mL (range, 3.24-178.54) on the sixth day and 22.62 μg/mL 12 (range, 0.00-129.58) on the eleventh day (p<0.01) ( Figure 2B ). The median serum FVP concentrations in patients with or without hyperuricemia (UA >10 mg/dL) at baseline were 0.00 μg/mL (range, 0.00-0.01) and 0.00 μg/mL (range, 0.00-0.02), respectively, which is expected as this is prior to the first dose of FVP. After FVP Figure 2C ).

The correlation between serum FVP and UA levels on the sixth day and the eleventh day was examined. The serum FVP and UA levels showed positive correlation on both days (r=0.52 on the sixth day, p<0.01; r=0.49 on the eleventh day, p<0.01) (Figures 3A, 3B) . To examine the factors associated with the occurrence of hyperuricemia, multivariate analysis was performed using the logistic regression analysis. Higher than median steady-state serum FVP concentrations (>48.31 μg/mL) and higher than median baseline serum UA levels (>4.6 mg/dL) were independent factors associated with the occurrence of hyperuricemia during FVP therapy (odds ratio for FVP concentration > median on the sixth day, 5,37 [95% CI, 1.70-17.00] and odds ratio for UA level > median at baseline, 3.58 [95% CI, 1.14-11.30]) ( Table 2) .

Since high serum FVP concentrations on the sixth day and high serum UA levels at baseline were independently associated with the occurrence of hyperuricemia during FVP therapy, we determined the cut-off value for the sixth-day serum FVP concentration which approximates the steady state and the baseline serum UA level by ROC curve analysis. An ROC curve identified that sixth-day serum Figures 4A, 4B ).

FVP is being evaluated as a potential oral treatment option for COVID-19. Transient elevation of serum UA levels occurs frequently with FVP therapy, but the risk factors for this event have not been comprehensively evaluated. This study investigated the factors associated with the occurrence of hyperuricemia during FVP therapy by using dataset and serum samples available from a previous clinical trial of this agent against COVID-19. The serum UA and FVP levels were increased during FVP therapy, and patients who presented with hyperuricemia during or right after FVP therapy were shown to have high serum FVP concentrations compared to patients who did not develop hyperuricemia. Furthermore, high serum FVP concentrations (>48.31 µg/ml) during FVP therapy and high baseline serum UA levels were independent factors associated with occurrence of hyperuricemia by FVP.

In the dose-response phase II study conducted in Japanese patients with influenza (JP205 Study), dose-dependent increase of serum UA levels was reported (Pharmaceuticals and Medical Devices Agency (PMDA), 2014). Our results correlating serum UA and FVP levels are consistent with this observation. FVP and its metabolite, M1, decrease UA secretion by inhibiting organic anion transporter (OAT) 1 and OAT3, which leads to decreased tubular secretion of UA, while M1 also enhances UA reabsorption of UA via urate transporter (URAT) 1 (Mishima et al., 2020, Pharmaceuticals and Medical Devices Agency (PMDA), 2014). In addition, patients with renal dysfunction usually have high serum UA levels and low urinary UA clearance (Li et al., 2018) . Thus, FVP-induced increase in UA levels might be influenced by renal function as well. In our study, however, baseline creatinine clearance in patients with hyperuricemia was comparable with that in patients without hyperuricemia, and creatinine clearance did not correlate with serum UA levels during FVP therapy (r=0.10, p=0.44; Supplementary Figure 2A ). Furthermore, creatinine clearance was moderately correlated with serum FVP concentrations during FVP therapy (r=-0.44, p<0.01;

Supplementary Figure 2B ). Therefore, serum FVP concentrations could be considered as a factor for hyperuricemia caused by FVP independent of renal function. The serum FVP concentrations as a cut-off value for hyperuricemia in the present study (48.3 μg/mL) were higher than in the previous 15 study (20 μg/mL) (Morikawa et al., 2021) . Since subjects in our study was younger (median age, 48.5) than in the previous study (median age, 63), the difference between the ages of subjects might have affected the UA levels. In addition, the UA levels after FVP administration in the previous study (6.6 to 9.3 mg/dL) were lower than that in our study. The risk of acute gouty arthritis is increased hyperuricemia (UA >10 mg/dL) (Wilson and Saseen, 2016) , therefore patients with history of acute gouty arthritis may benefit from monitoring of the UA level. Furthermore, our cut-off value might be useful in predicting elevation of UA level during FVP therapy.

High baseline serum UA levels were predictive of subsequent hyperuricemia (UA levels >10 mg/dL) during FVP therapy. There are few reports on the effect of serum UA levels prior to FVP therapy on subsequent levels on therapy. One study reported that baseline serum UA levels had no effect on laboratory values during FVP administration, but it did not examine the correlation between baseline serum UA levels and those during FVP therapy (Inkaya et al., 2021) . ROC analysis revealed that baseline serum UA levels >3.7 mg/dL were predictive of hyperuricemia, which suggests that not only patients with overt hyperuricemia but also those with serum UA levels at the upper end of the normal range should be aware of the risk of hyperuricemia and its associated symptoms such as gout attacks that may occur with FVP therapy.

Our study has several limitations. First, blood was collected primarily for safety evaluation as part of the underlying clinical trial and collection was not necessarily timed with FVP administration. In a Japanese phase I study for influenza (JP118 Study), in which FVP was orally administered at 1,200 mg twice daily on the first day, followed by 600 mg orally administered twice daily for additional five days, the serum FVP concentrations at completion of FVP administration (mean ± SD) were approximately C min 20 ± 20 μg/mL and C max 60 ± 30 μg/mL (Pharmaceuticals and Medical Devices Agency (PMDA), 2014). Despite the higher FVP dose, the median FVP concentration at the same time point in our study (48.31 μg/mL [range, 3.24-178 .54]) did not differ substantially from the that assumed from the JP118 Study. It should therefore be noted that, while the timing of blood draw relative to FVP dosing was not standardized, this does not appear to fully account for this observation. Second, the specificity of baseline serum UA level in predicting hyperuricemia was limited in the ROC analysis. This was in part due to prioritization of sensitivity since measurement of UA levels is relatively routine and inexpensive. Third, serum ferritin levels were not measured in the present study. Since ferritin levels are inversely associated with blood FPV levels (Morikawa et al., 2021) , further studies to assess the impact of ferritin levels is needed.

In conclusion, patients with COVID-19 who have high baseline serum UA levels and those who show high serum FVP concentrations during FVP treatment are susceptible to hyperuricemia induced by FVP. Not only patients with hyperuricemia, but also patients with high baseline serum UA levels within the normal range may be at elevated risk for developing hyperuricemia during FVP administration. Additionally, serum FVP concentrations might be a factor to consider for the occurrence of hyperuricemia during FVP therapy.

This research was supported by grants from the Japan Agency for Medical Research and Development (AMED) under Grant Number 19fk0108150s0001 and 20fk0108150s0001.

Y.D. has served on a scientific advisory board of, and received speaking fee from, FujiFilm Toyama Chemical, the manufacturer of favipiravir in Japan. The other authors declare that they have no conflicts of interests.

This study was approved by the Institutional Review Board of Fujita Health University (HM20-169).

TK, YD and TM conceived and designed the study. HI and KN performed the experimental work.

TK and TM contributed to statistical analysis. SY and KT contributed to the study concept and design. TK, YD and TM drafted the manuscript. All authors contributed to the critical input and endorsed the final version of the manuscript. Baseline serum UA >4.6 mg/dL 3.58 1.14-11.30 0.029 BMI, body mass index; CI, confidence interval; FVP, favipiravir; OR, odds ratio; UA, uric acid.

Therapeutic Effectiveness and Safety of Repurposing Drugs for the Treatment of COVID-19: Position Standing in 2021

A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19

Acute Gouty Arthritis During Favipiravir Treatment for Coronavirus Disease

Pretreatment serum uric acid level is not a surrogate marker for the outcome of favipiravir treatment in COVID-19 patients

Investigation of the freely available easy-to-use software 'EZR' for medical statistics

Urinary excretion of uric acid is negatively associated with albuminuria in patients with chronic kidney disease: a cross-sectional study

Uric Acid Elevation by Favipiravir, an Antiviral Drug

Elevated blood favipiravir levels are inversely associated with ferritin levels and induce the elevation of uric acid levels in COVID-19 treatment: A retrospective single-center study

A review of the safety of favipiravir -a potential treatment in the COVID-19 pandemic?

Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial

Gouty Arthritis: A Review of Acute Management and Prevention

Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial

Hyperuricemia (UA, >10mg/dL) (n=4

WBC, white blood cell; BMI, body mass index; CRP, C-reactive protein

 18 We thank Masahiro Suzuki for helping with processing of the serum samples, and Eishi Imoto (Shimadzu Corporation) for validating the LC-MS method for quantifying FVP.